RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial

The purpose of the study is to assess the safety and effectiveness of the BioVentrix Revivent System plus GDMT compared to GDMT alone for the treatment of LV anterior/apical scar/aneurysm with possible additional involvement of the lateral, septal, and/or inferior regions in patients with symptomatic heart failure.

Safety will be assessed compared with a Performance Goal based on surgical ventriculoplasty outcomes (MAE's at 30 days).

Inclusion criteria

• 18 years old or older
• LV Aneurysm or Scar Presence: Defined by presence of a contiguous acontractile (akinetic and/or dyskinetic) non-calcified scar
• LV Aneurysm/Scar Location: Defined as a scar involving anterior, apical or anterolateral ± septal regions of the left ventricle as evidenced by cardiac imaging (Viability of myocardium in regions remote from area of intended scar exclusion as evidenced by cardiac imaging)
• Left Ventricular Ejection Fraction < 40%
• Left ventricular end-systolic volume index ≥60 mL/m2
• Suffering from heart failure symptoms as defined by NYHA Classification > 2 not responsive to medical therapy
• Patient completed 6 Minute Walk Test and KCCQ Quality of Life Questionnaire (can be performed at baseline visit)
• Patient is on adequate Guideline Directed Medical Therapy (GDMT)
• Subject or a legally authorized representative must provide written informed consent
• Agree to required follow-up visits
• Female subject of childbearing potential does not plan pregnancy for at least one year following the index procedure. For a female of childbearing potential, a pregnancy test must be performed with negative results known within seven days prior to index procedure

Exclusion criteria

Candidates will be excluded from the study if ANY of the following conditions is present:

• Cardiac Resynchronization Therapy (CRT) or ICD pacing lead placement ≤ 90 days prior to enrollment
• Valvular heart disease, which in the opinion of the investigator, will require intervention (transcatheter or surgical)
• Mitral Regurgitation greater than moderate (>2+)
• Need for coronary revascularization, in the opinion of the investigator
• Peak Systolic Pulmonary Arterial Pressure > 70 mm Hg via echo or right heart catheterization
• Myocardial Infarction within 90 days prior to enrollment
• Within the last six months, a prior CVA or TIA, or intracranial hemorrhage
• Co-morbid disease process with life expectancy of less than one year or active malignancy not in remission
• Severe pulmonary disease that would preclude general anesthesia
• Any solid organ transplant or is on waiting list for any solid organ transplant other than cardiac
• Chronic renal failure with a GFR<30ml/min
• Subject is currently participating in another clinical trial that has not yet completed its primary endpoint